Welcome to our dedicated page for Pharming Group N.V. news (Ticker: PHAR), a resource for investors and traders seeking the latest updates and insights on Pharming Group N.V. stock.
Pharming Group N.V. ADS (PHAR) generates a steady flow of news related to rare disease biopharmaceuticals, including commercial updates, clinical trial milestones, regulatory decisions, and financial results. As a global company focused on hereditary angioedema (HAE) and activated phosphoinositide 3‑kinase delta syndrome (APDS), its announcements often center on RUCONEST for acute HAE attacks and Joenja (leniolisib), an oral PI3Kδ inhibitor for APDS.
Investors following PHAR news can expect regular updates on regulatory progress for leniolisib, such as U.S. FDA approvals, Priority Review designations, and submissions in regions including the European Economic Area, the U.K., Japan, and other markets. Pharming also reports on Phase III pediatric trials of leniolisib in children with APDS and Phase II studies in broader primary immunodeficiency populations, as well as scientific publications that refine APDS diagnosis through genetic variant classification.
Company communications frequently include commercial performance highlights, with quarterly and half‑year financial reports detailing revenue contributions from RUCONEST and Joenja, geographic breakdowns, and commentary on patient and prescriber trends. Pharming also issues news about participation in healthcare and investor conferences, scientific meetings, and presentations of new data on HAE and APDS.
For readers tracking PHAR, this news stream provides insight into how Pharming is advancing its rare disease portfolio, expanding access to Joenja and RUCONEST, and executing on its strategy as a dual‑listed mid‑cap biopharmaceutical company. Bookmarking the news page allows investors, analysts, and healthcare professionals to monitor key catalysts, including clinical readouts, regulatory milestones, and major corporate developments disclosed in press releases and Form 6‑K filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pharming Group N.V. (Euronext Amsterdam: PHARM, Nasdaq: PHAR) has announced the first commercial shipments of Joenja® (leniolisib) to patients in the United States. Joenja® is the first and only approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency affecting adults and children aged 12 and older. The commencement of these shipments triggers a $10 million milestone payment to Novartis, under a 2019 licensing agreement. Joenja® was recently approved by the FDA, and the company aims to make it widely available across the U.S. Additionally, leniolisib is undergoing further regulatory reviews in Europe, the UK, Canada, Australia, and Japan, with ongoing clinical trials for younger patients suffering from APDS.
Pharming Group N.V. announced participation in the Guggenheim Healthcare Talks focused on Genomic Medicines and Rare Disease Days, scheduled for April 3-4, 2023, in New York. CEO Sijmen de Vries and CCO Stephen Toor will feature in a fireside chat on April 3 at 15:20 ET. Interested investors can access a live webcast and replay on Pharming's website. Additionally, they will be available for one-on-one meetings during the conference. Pharming is dedicated to developing treatments for rare diseases and operates globally, serving patients in over 30 markets.
Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) as the first and only treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older. This milestone treatment, expected to launch in early April, was developed under priority review due to its potential to improve outcomes for patients with this rare disease. Joenja® demonstrated significant clinical efficacy in a Phase II/III trial. Pharming will incur milestone payments of approximately $10.5 million to Novartis upon approval and additional sales-based payments up to $190 million.
Pharming Group N.V. has announced the enrollment of the first patient in its Phase III clinical trial (NCT05438407) for leniolisib, aimed at treating children with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare genetic disorder. The trial will assess leniolisib's safety, efficacy, and tolerance in approximately 15 children aged 4 to 11 years across the U.S., Europe, and Japan. Primary efficacy endpoints include reducing lymph node size and increasing naïve B cell counts after 12 weeks. A subsequent trial for younger children (aged 1-6) is planned for Q3 2023. Leniolisib has shown promise in prior studies, and regulatory reviews are ongoing for broader approval.
FAQ
What is the current stock price of Pharming Group N.V. (PHAR)?
What is the market cap of Pharming Group N.V. (PHAR)?
